A number of firms have modified their ratings and price targets on shares of Endo International (NASDAQ: ENDP) recently:

  • 1/3/2018 – Endo International had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $12.00 price target on the stock, down previously from $14.00. They wrote, “We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued.””
  • 1/2/2018 – Endo International is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $12.00 price target on the stock.
  • 12/31/2017 – Endo International was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 12/26/2017 – Endo International was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $8.92 price target on the stock.
  • 12/18/2017 – Endo International was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $8.92 price target on the stock.
  • 12/12/2017 – Endo International was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/12/2017 – Endo International is now covered by analysts at Guggenheim. They set a “neutral” rating and a $8.50 price target on the stock.
  • 11/10/2017 – Endo International had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $7.00 price target on the stock.
  • 11/10/2017 – Endo International had its “buy” rating reaffirmed by analysts at Mizuho. They wrote, “We will update our rating and PT later. We summarize 3Q:17 performance in Exhibit 1.””
  • 11/10/2017 – Endo International had its price target lowered by analysts at BMO Capital Markets from $11.00 to $10.00. They now have a “market perform” rating on the stock.
  • 11/10/2017 – Endo International had its price target lowered by analysts at Cantor Fitzgerald from $9.00 to $7.00. They now have a “neutral” rating on the stock.
  • 11/10/2017 – Endo International had its price target lowered by analysts at Citigroup Inc from $9.00 to $7.00. They now have a “neutral” rating on the stock.
  • 11/10/2017 – Endo International had its price target lowered by analysts at Royal Bank of Canada from $9.00 to $8.00. They now have a “sector perform” rating on the stock.

Shares of Endo International plc – (NASDAQ ENDP) traded down $0.41 on Tuesday, reaching $8.17. 10,772,444 shares of the company’s stock traded hands, compared to its average volume of 8,001,999. The firm has a market capitalization of $1,920.00, a P/E ratio of -0.42, a price-to-earnings-growth ratio of 2.98 and a beta of 0.59. Endo International plc – has a 52 week low of $5.77 and a 52 week high of $16.73. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.01 earnings per share. research analysts anticipate that Endo International plc – will post 3.67 earnings per share for the current fiscal year.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International plc - and related companies with MarketBeat.com's FREE daily email newsletter.